Researchers at the University of California, San Francisco have achieved a significant breakthrough in CAR T cell therapy by developing a method to create these engineered immune cells in vivo, rather than the traditional in vitro approach. Utilizing a CRISPR-based system, they successfully inserted a chimeric antigen receptor (CAR) directly into T cells within living mice, leading to enhanced efficacy against various cancers, including leukemia and solid tumors.

This innovative approach addresses key limitations of current CAR T therapies, which often involve lengthy and costly processes that can lead to variable outcomes. By generating CAR T cells within the body, the researchers demonstrated not only improved expansion and functionality of the cells but also a reduction in the time and resources required for treatment. Their findings suggest that in vivo CAR T cells maintain a more robust “stemness” and proliferative capacity compared to those created in laboratory settings, potentially leading to better patient outcomes.

The implications of this research are profound. If this in vivo method can be successfully translated to human applications, it could democratize access to CAR T therapies, making them more affordable and widely available, even in community hospitals. This advancement holds the promise of significantly improving treatment options for patients with aggressive cancers who currently have limited alternatives.

Source: lifespan.io